Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Submits Premarket Approval Application to FDA for Sequencing-Based Companion Dx

NEW YORK (GenomeWeb) – Thermo Fisher Scientific has submitted a premarket approval application to the US Food and Drug Administration for a next-generation sequencing-based companion diagnostic, the company said today.

The firm submitted an application for its Oncomine Universal Dx test for non-small cell lung cancer that it developed in partnership with Novartis and Pfizer. The test will use the Ion AmpliSeq technology and run on the Ion Torrent PGM Dx system.

"As pharmaceutical companies shift toward developing new targeted therapies as opposed to "one-size-fits-all" drugs, there is a clear need to more efficiently stratify cancer patients and tailor their treatments to enable better health outcomes," Joydeep Goswami, president of clinical next-generation sequencing at Thermo Fisher, said in a statement.

The universal CDx would analyze multiple markers from a formalin-fixed paraffin-embedded tumor sample and would deliver results in five days with 10 nanograms of DNA, according to Thermo Fisher.

The PMA submission includes clinical and analytical claims associated with NSCLC biomarkers following clinical trials completed by Novartis and Pfizer. In addition, representatives from Thermo Fisher, Pfizer, and Novartis said at a recent conference that other pharmaceutical companies could join in the collaboration, since the CDx likely includes targets being investigated by other pharma firms. The companies also plan to work together to market the assay.

Illumina is also developing a universal CDx in collaboration with AstraZeneca, Janssen Biotech, and Sanofi. Illumina has not yet submitted a PMA for the universal CDx to the FDA, but earlier this month said that it had submitted a separate CDx that it developed with Amgen to the FDA.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.